Generic drug
Estrogens, conjugated (USP) / medroxyprogesterone price, strengths & recalls
Pharmacies pay $8.68 for 1 kit of Estrogens, conjugated (USP) / medroxyprogesterone 28 day pack this week, and from $8.68 to $243.41 across its 5 priced strengths and forms. Its official label last changed on April 29, 2026.
Generic- Fair cash price
- $20.48
- Strengths
- 5
- Makers
- 1
- Updated
- Nov 11
Estrogens, conjugated (USP) / medroxyprogesterone price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.3/1.5 28 day pack | $8.68 | $243.02 / 28 tablets |
| 0.45/1.5 28 day pack | $8.69 | $243.41 / 28 tablets |
| 0.625/2.5 28 day pack | $8.68 | $242.91 / 28 tablets |
| 0.625/5 28 day pack | $8.67 | $242.66 / 28 tablets |
| 28 day pack | $8.68 | $8.68 / 1 kit |
The lowest cost per tablet is 0.625/5 28 day pack at $8.67. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Supply status: shortages & recalls
What people paid for Estrogens, conjugated (USP) / medroxyprogesterone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use PREMPRO/PREMPHASE safely and effectively. See full prescribing information for PREMPRO/PREMPHASE.PREMPRO® (conjugated estrogens/medroxyprogesterone acetate tablets) PREMPHASE® (conjugated estrogens plus medroxyprogesterone acetate tablets)Initial U.S. Approval: 1995
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.6, 14.7)].
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.6)].
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.7)].
Breast Cancer
The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.6)].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen-Alone Therapy
Endometrial Cancer
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].
Cardiovascular Disorders and Probable Dementia
Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.6, 14.7)].
The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.6)].
The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.7)].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA
See full prescribing information for complete boxed warning.
Estrogen Plus Progestin Therapy
•
Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)
•
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI) (5.1)
•
The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2)
•
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
Estrogen-Alone Therapy
•
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (5.2)
•
Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)
•
The WHI estrogen-alone substudy reported increased risks of stroke and DVT (5.1)
•
The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA020527 · Wyeth Pharms
- First approved
- November 17, 1995 (31 years ago)
- Latest approved change
- April 22, 2025
- Approved label
- PDF, Apr 24, 2025
- Generic makers
- None on the market
Estrogens, conjugated (USP) / medroxyprogesterone questions
How much does estrogens, conjugated (usp) / medroxyprogesterone cost without insurance?
Pharmacies pay about $8.68 for 1 kit of estrogens, conjugated (usp) / medroxyprogesterone 28 day pack ($8.68 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $20.48. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is estrogens, conjugated (usp) / medroxyprogesterone in shortage?
No shortage is reported for estrogens, conjugated (usp) / medroxyprogesterone right now. We check the national shortage list every day.
Has estrogens, conjugated (usp) / medroxyprogesterone been recalled?
No recalls are on record for estrogens, conjugated (usp) / medroxyprogesterone.
When did the estrogens, conjugated (usp) / medroxyprogesterone label last change?
The official label was last updated on April 29, 2026 (version 39). See what changed.
Talk about estrogens, conjugated (usp) / medroxyprogesterone
No comments yet. Questions, tips, what worked for you - start the conversation.